Dan Stanton
Journalist at Freelance
Editor at BioProcess International Magazine
B2B journo focused on biopharma & bioprocessing industry. Information is not knowledge, knowledge is not wisdom. Opinions are all mine and probably not yours
Articles
-
2 weeks ago |
bioprocessintl.com | Dan Stanton
In October 2022, Germany’s Merck opened a €50 million ($55 million) plant at its Martillac site, south of Bordeaux, to support its contract development and manufacturing organization (CDMO) business. The 2,700 square-meter single-use plant has the capacity to produce commercial monoclonal antibody and recombinant protein drug substance up to the 2,000 L scale, based on single-use systems.
-
4 weeks ago |
bioprocessintl.com | Dan Stanton
Amid the threat of tariffs, J&J has pledged $55bn in US investment over the next four yearsDepositPhotos/volodymyr.martynJ&J officially broke ground on the 500,000 square-foot biologics facility last Friday, with the site expected to expand capacity for the large pharma’s cancer, immune-mediated, and neurological disease portfolio and future pipeline.
-
1 month ago |
bioprocessintl.com | Dan Stanton
In the first quarter this year, there was only one US approval in the CGT space – Neurotech’s Encelto (revakinagene taroretcel). And according to US Food and Drug Administration (FDA) approval target dates for the rest of the year, only one cell therapy and three gene therapies are on the calendar, though not all Prescription Drug User Fee Act (PDUFA) dates are public.
-
1 month ago |
bioprocessintl.com | Dan Stanton
The Karnataka, India-based company has been doing the rounds on the conference circuit this week, telling both DCAT and BIO-Europe Spring delegates about its jump into the contract development and manufacturing organization (CDMO) space. Despite the busy PR-push, BioProcess International caught up with Shilpas’s CEO Sridevi Khambhampaty by email, who told us the move comes as the company seeks to capitalize on resurging biotech funding and the growing trend for supply chain diversification.
-
1 month ago |
bioprocessintl.com | Dan Stanton
Sanofi’s implementation of Industry 4.0-based elements – including AI and digitization – is crucial for driving productivity within its manufacturing network but reliant on contextualized data. In the pursuit of producing roughly 4.3 billion units of medicines and vaccines per year, French pharma giant Sanofi invests roughly €1 billion annually to transform and modernize its Manufacturing & Supply (M&S) division.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 4K
- DMs Open
- No
2 things i said i wouldn't do in 2024: a) use Musk' toXic Twitter platform and b) go to #CPHImilan #CPHI . Well here i am. As are 40,000 others all trying to get in https://t.co/kRdA4wfTJv
Large crowd at #BPIeurope attending the LiveLabs tour... currentluly hearing about @benchling process management software offerings https://t.co/dSDxtaXRIO
if you aint an insider then you're an outsider... or @BioProInsider team hard at work at ##BPIEUROPE https://t.co/EXsM6WmCrY